ClinicalTrials.gg
CompletedNCT04961190Updated Nov 20, 2026

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

A Phase 4 interventional study of Prolonged Exposure Therapy and Pharmacotherapy with paroxetine or venlafaxine XR in Posttraumatic Stress Disorder, sponsored by University of Pennsylvania. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Stress Disorders, Post-Traumatic by University of Pennsylvania — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of Pennsylvania.

Enrollment
4th of 19
304 · median 128
Started
2022
the only one that year
Phase 4
2 of 19
none open now
Registered
15th of 19
by date

Among the 19 studies in Stress Disorders, Post-Traumatic by University of Pennsylvania, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 4, and was the 15th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 19 studies in Stress Disorders, Post-Traumatic by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Stress Disorders, Post-Traumatic by University of Pennsylvania, or all of them as a file.
02

Study summary

Posttraumatic Stress Disorder (PTSD) remains a salient and debilitating problem, in the general population and for military veterans in particular. Several psychological and pharmacological treatments for PTSD have evidence to support their efficacy. However, the lack of comparative effectiveness data for PTSD treatments remains a major gap in the literature, which limits conclusions that can be drawn about which of these treatments work best. The current study will compare the effectiveness of PTSD treatments with the strongest evidentiary support - Prolonged Exposure (PE) therapy and pharmacotherapy with paroxetine or venlafaxine - as well as the combination of these two treatments. A randomized trial will be conducted with a large, diverse sample of veterans with PTSD (N = 300) recruited from 6 VA Medical Centers throughout the US. Participants will complete baseline assessments, followed by an active treatment phase (involving up to 14 sessions of PE and/or medication management) with mid (7 week) and posttreatment (14 week) assessments, and follow-up assessments at 27 and 40 weeks. Study outcomes will include PTSD severity, depression, quality of life and functioning, assessed via clinical ratings and self-report measures. Further, a range of demographic and clinically relevant variables (e.g., trauma type/number, resilience) will be collected at baseline and examined as potential predictors or moderators of treatment response, addressing another gap in the PTSD treatment literature. These data will be used to develop algorithms from predicting the optimal treatment for individual patients (i.e., "personalized advantage indices"; PAIs). Effectiveness of the treatments will be compared using multilevel modeling. PAIs will be developed by conducting bootstrapped analyses to select variables that predict or moderate outcomes (clinician rated PTSD severity at Week 14), followed by jacknife analyses to determine the magnitude of the predicted difference (representing an individual's "predicted advantage" of one treatment over the others).

Read the detailed description

Posttraumatic Stress Disorder (PTSD) remains a salient and debilitating problem, in the general population and for military veterans in particular. Several psychological and pharmacological treatments for PTSD have evidence to support their efficacy. However, the lack of comparative effectiveness trials for PTSD treatments remains a major gap in the literature, which limits conclusions that can be drawn about which of these treatments work best. In particular, trials directly comparing efficacious psychotherapies and pharmacotherapies are needed to inform clinical decision making for patients and providers. To address this gap, the proposed study will aim to compare the effectiveness of PTSD treatments with the strongest evidentiary support - Prolonged Exposure (PE) therapy and pharmacotherapy with paroxetine or venlafaxine - as well as the combination of these two treatments. A randomized trial in proposed with a large, diverse sample of veterans with PTSD (N = 300) recruited from 6 Veterans Affairs Medical Centers throughout the US (in Philadelphia, Coatesville, Milwaukee, Dallas, San Diego, and Palo Alto). Treatments conditions will reflect "real world" practice in these settings, and minimal exclusion criteria related to safety will be adopted, to maximize external validity. Participants will be permitted to complete treatment sessions in person or via telehealth (based on evidence for equivalent outcomes across these modalities), to maximize patient access, recruitment, and generalizability. Participants will complete baseline assessments, followed by 14 weeks of active treatment (involving up to 14 sessions of PE and/or medication management) with mid and posttreatment assessments after 7 and 14 weeks respectively, and then follow-up assessments at 27 and 40 weeks. Primary outcomes will include PTSD severity, depression symptoms, quality of life and functioning, assessed via clinical ratings and self-report measures. Further, a range of demographic and clinically relevant variables (e.g., trauma type/number, physiological arousal) will be collected at baseline and examined as potential predictors or moderators of treatment response, addressing another key gap in the PTSD treatment literature. Specifically, these data will be used to develop algorithms from predicting the optimal treatment for individual patients (i.e., "personalized advantage indices"; PAIs), a statistical approach which has advanced the depression treatment literature but has only been used in a limited capacity in PTSD research. The project will include an Advisory Board composed of clinician and patient representatives, in order to obtain stakeholder feedback at every stage of the study (from implementation to dissemination of findings). The effectiveness of the treatments will be compared using multilevel modeling. PAIs will be developed by conducting bootstrapped analyses to select variables that predict or moderate outcomes (Clinician Administered PTSD Scale severity ratings at Week 14), followed by leave-one-out cross-validation (i.e., jackknife) analyses to determine the magnitude of the predicted difference that results in each analysis representing that individuals "predicted advantage" (of one treatment over the others). We hypothesize that individuals who receive PE will have better outcomes than those who receive pharmacotherapy alone, based on existing data (e.g., cross study effect size comparisons), but have planned the study and sample to maximize statistical power in all analyses.

03

Conditions studied

  • Posttraumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of Posttraumatic Stress Disorder
  • military veteran
  • fluent in English
  • willing to participate in PE, pharmacotherapy, or both
  • capable of providing

Exclusion criteria

Exclusion Criteria:

  • suicidal ideation with intent and/or plan, or suicidal behavior in the past month
  • active psychosis
  • history of manic episode(s)
  • a failed trial of Prolonged Exposure therapy or paroxetine and venlafaxine XR
  • ongoing medical conditions or treatments that would contraindicate initiating these treatments (e.g., medications that have potential interactions with paroxetine and venlafaxine such as MAO inhibitors)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
304 participants (actual)

Study arms

  • Active comparator
    Prolonged Exposure Therapy

    8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders

    Behavioral: Prolonged Exposure Therapy

  • Active comparator
    Pharmacotherapy

    20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily

    Drug: Pharmacotherapy with paroxetine or venlafaxine XR

  • Active comparator
    Combined treatment (Prolonged Exposure and Pharmacotherapy)

    8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily

    Behavioral: Prolonged Exposure Therapy · Drug: Pharmacotherapy with paroxetine or venlafaxine XR

Interventions

  • BehavioralProlonged Exposure Therapy

    A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders

  • DrugPharmacotherapy with paroxetine or venlafaxine XR

    Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression

    Also known as: Pharmacotherapy with Paxil or Effexor XR

06

What researchers measure

Primary outcomes

  1. Change during active treatment on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 is a structured clinical interview that assesses the presence and severity of PTSD symptoms. Twenty items are rated on a 5-point scale from 0 (absent) to 4 (extremely/incapacitating). Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity

    Time frame: baseline to 14 weeks

  2. Change during follow-up on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 is a structured clinical interview that assesses the presence and severity of PTSD symptoms. Twenty items are rated on a 5-point scale from 0 (absent) to 4 (extremely/incapacitating). Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity

    Time frame: 14 weeks to 40 weeks

  3. Change during active treatment on the PTSD Checklist for DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-report measure examining the presence and severity of recent PTSD symptoms using a 0 (not at all) to 4 (extremely) point Likert scale. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

    Time frame: baseline to 14 weeks

  4. Change during follow-up on the PTSD Checklist for DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-report measure examining the presence and severity of recent PTSD symptoms using a 0 (not at all) to 4 (extremely) point Likert scale. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

    Time frame: 14 weeks to 40 weeks

Secondary outcomes

  1. Change during active treatment on the Quick Inventory of Depressive Symptoms - clinician rated (QIDS-C)

    The QIDS is a structured interview that assesses presence and severity of depressive disorder symptoms. Sixteen items are rated on a 0-3 scale and summed. Total scores range from 0 to 27 (higher scores indicate greater depression symptom severity).

    Time frame: baseline to 14 weeks

  2. Change during follow-up on the Quick Inventory of Depressive Symptoms - clinician rated (QIDS-C)

    The QIDS is a structured interview that assesses presence and severity of depressive disorder symptoms. Sixteen items are rated on a 0-3 scale and summed. Total scores range from 0 to 27 (higher scores indicate greater depression symptom severity).

    Time frame: 14 weeks to 40 weeks

  3. Change during active treatment on the Patient Health Questionnaire depression module (PHQ-9)

    This self-report inventory consists of 9 items that assess depressive symptoms over the past 2 weeks using a scale from 0 (not at all) to 3 (nearly every). Total scores range from 0 to 27, with higher scores indicating greater depression symptom severity.

    Time frame: baseline to 14 weeks

  4. Change during follow-up on the Patient Health Questionnaire depression module (PHQ-9)

    This self-report inventory consists of 9 items that assess depressive symptoms over the past 2 weeks using a scale from 0 (not at all) to 3 (nearly every). Total scores range from 0 to 27, with higher scores indicating greater depression symptom severity.

    Time frame: 14 weeks to 40 weeks

  5. Change during active treatment on the Social and Occupational Functioning Assessment Scale (SOFAS)

    The SOFAS is a global clinical rating scale of current functioning, ranging from 0 to 100 (with higher scores indicated better functioning), which focuses on impairments in social and occupational functioning caused by physical and mental health problems (rated independent of symptom severity).

    Time frame: baseline to 14 weeks

  6. Change during follow-up on the Social and Occupational Functioning Assessment Scale (SOFAS)

    The SOFAS is a global clinical rating scale of current functioning, ranging from 0 to 100 (with higher scores indicated better functioning), which focuses on impairments in social and occupational functioning caused by physical and mental health problems (rated independent of symptom severity).

    Time frame: 14 weeks to 40 weeks

  7. Change during active treatment on the Veterans RAND 12-item Health Survey (VR-12)

    This brief self-report scale was developed (with modified items from the 36 item Short-Form Health Survey) and validated specifically for veterans to assess health-related quality of life, based on reported functioning in multiple domains (e.g., general health, social activities, role limitations). Patients receive a physical component score and a mental component score, and both are scaled so that a score of 50 corresponds to the population average (higher scores indicate better quality of life).

    Time frame: baseline to 14 weeks

  8. Change during follow-up on the Veterans RAND 12-item Health Survey (VR-12)

    This brief self-report scale was developed (with modified items from the 36 item Short-Form Health Survey) and validated specifically for veterans to assess health-related quality of life, based on reported functioning in multiple domains (e.g., general health, social activities, role limitations). Patients receive a physical component score and a mental component score, and both are scaled so that a score of 50 corresponds to the population average (higher scores indicate better quality of life).

    Time frame: 14 weeks to 40 weeks

07

Study locations

7 sites
08

References and documents

Publications

  • Bredemeier K, Larsen S, Shivakumar G, Grubbs K, McLean C, Tress C, Rosenfield D, DeRubeis R, Xu C, Foa E, Morland L, Pai A, Tsao C, Crawford J, Weitz E, Mayinja L, Feler B, Wachsman T, Lupo M, Hooper V, Cook R, Thase M. A comparison of prolonged exposure therapy, pharmacotherapy, and their combination for PTSD: What works best and for whom; study protocol for a randomized trial. Contemp Clin Trials. 2022 Aug;119:106850. doi: 10.1016/j.cct.2022.106850. Epub 2022 Jul 13. PubMed 35842108 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Oct 2026, 52 months.

Of 30 non-industry phase 4 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 71. This study's 52 months is close to that.

Counting every sponsor, half of 31 studies reached it within 52 months; a quarter within 36 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jul 14, 2021
StartActual
May 25, 2022
Primary completionActual
Oct 23, 2026was Nov 2026
CompletionActual
Oct 23, 2026was Nov 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 20, 2026
Primary completion
Nov 1, 2026→Oct 23, 2026 (actual)
Nov 20, 2026
Study completion
Nov 1, 2026→Oct 23, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Active, not recruiting→Completed
    Primary completion Nov 1, 2026→Oct 23, 2026 (now actual)
    Study completion Nov 1, 2026→Oct 23, 2026 (now actual)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04961190
Collaborators
Patient-Centered Outcomes Research Institute, Corporal Michael J. Crescenz VA Medical Center, Coatesville VA Medical Center, Milwaukee VA Medical Center, North Texas Veterans Healthcare System, San Diego Veterans Healthcare System, VA Palo Alto Health Care System, Birmingham VA Health Care System
Responsible party
Sponsor
First posted
Jul 14, 2021
Start date
May 25, 2022
Primary completion
Oct 23, 2026
Completion
Oct 23, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion